Advances on early application of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome
Low-density lipoprotein cholesterol(LDL-C)is one of the major risk factors for coronary heart disease(CHD)and is closely related to adverse outcomes in CHD patients.Proprotein convertase subtilisin/kexin type 9(PCSK9)plays an important role in regulating cholesterol metabolism.PCSK9 inhibitors can increase the number of LDL-C receptors on cell membranes by inhibiting PCSK9,significantly lowering plasma LDL-C lev-els.This reduction helps to decrease the occurrence of adverse cardiovascular events in CHD patients.This study summarizes the theoretical basis for using PCSK9 inhibitors to improve atherosclerosis and highlights their clinical benefits in patients with acute coronary syndrome.This provides justification for implementing intensified lipid-lowering therapy with PCSK9 inhibitors in this patient population.
proprotein convertase subtilisin/kexin type 9 inhibitorsacute coronary syndromelow density lipo-protein cholesterolinflammatory responseplateletsmajor adverse cardiac events
NETL
NSTL
万方数据
